Guidance for Optimal Port Placement in Pure 3‐Dimensional Laparoscopic Donor Right Hepatectomy
Jeong‐Moo Lee, Ahmed Shehta, Kyung‐Suk Suh, Suk Kyun Hong, Kyung Chul Yoon, Jae‐Hyung Cho, Nam‐Joon Yi, Kwang‐Woong Lee – 26 July 2019
LiverLearning®: 2019 Webinar: The 2018 Primary Biliary Cholangitis Practice Guidance: Highlights
In this webinar, Drs. Marlyn Mayo and Cynthia Levy will discuss the most important recommendations included in the 2018 PBC Practice Guidance document. We will utilize a prerecorded webinar format for on-demand viewing on Liver Learning ® .Cynthia Levy Cynthia Levy, MD, FAASLD is a Professor of Medicine in the Division of Digestive Health and Liver Diseases and is the Associate Director of the Schiff Center for Liver Diseases at the University of Miami. She was awarded the Arthur Hertz Endowed Chair in Liver Diseases. Dr. Levy received her M.D.
Letter to the Editor: Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: Benefit or Not
Fang Luo, Rui Liao – 25 July 2019
The Impact of Coronary Artery Disease and Statins on Survival After Liver Transplantation
Samarth S. Patel, Viviana A. Rodriguez, Mohammad B. Siddiqui, Masoud Faridnia, Fei‐Pi Lin, Anchalia Chandrakumaran, John Laurenzano, Joseph Clinton, Gurukripa N. Kowlgi, Danielle Kirkman, Adam P. Sima, Erika Liptrap, Chandra Bhati, Mohammad Shadab Siddiqui – 25 July 2019 – Cardiovascular disease (CVD) is a major contributor to longterm mortality after liver transplantation (LT) necessitating aggressive modification of CVD risk.
Reply
Mussarat N. Rahim, Michael A. Heneghan – 25 July 2019
Role of Living Donor Liver Transplantation in Acute Liver Failure
Amar Gupta, Sumeet K. Asrani – 25 July 2019
Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase‐A/5‐Hydroxytryptamine/5‐Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis
Konstantina Kyritsi, Lixian Chen, April O’Brien, Heather Francis, Travis W. Hein, Julie Venter, Nan Wu, Ludovica Ceci, Tianhao Zhou, David Zawieja, Anatoliy A. Gashev, Fanyin Meng, Pietro Invernizzi, Luca Fabris, Chaodong Wu, Nicholas J. Skill, Romil Saxena, Suthat Liangpunsakul, Gianfranco Alpini, Shannon S. Glaser – 25 July 2019
Reply
Xiu‐Ping Zhang, Yu‐Zhen Gao, Zhen‐Hua Chen, Shu‐Qun Cheng – 25 July 2019
Surgical Management of Ciliated Hepatic Foregut Cyst
Ioannis A. Ziogas, Dirk J. Windt, Gregory C. Wilson, Alessandro Furlan, Michael A. Nalesnik, Samer Tohme, David A. Geller – 25 July 2019
Redefining Cirrhotic Cardiomyopathy for the Modern Era
Manhal Izzy, Lisa B. VanWagner, Grace Lin, Mario Altieri, James Y. Findlay, Jae K. Oh, Kymberly D. Watt, Samuel S. Lee, on behalf of The Cirrhotic Cardiomyopathy Consortium – 25 July 2019 – Cirrhotic cardiomyopathy (CCM) is cardiac dysfunction in patients with end‐stage liver disease in the absence of prior heart disease. First defined in 2005 during the World Congress of Gastroenterology, CCM criteria consisted of echocardiographic parameters to identify subclinical cardiac dysfunction in the absence of overt structural abnormalities.